SubHero Banner
Text

Dupixent® (dupilumab) – New indication

June 20, 2025 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP).

Download PDF